Boston Scientific Cuts Full-Year Profit Outlook Amid Slower Watchman Demand
Boston Scientific reported second-quarter net sales of $5.44 billion and adjusted earnings per share (EPS) of $0.86, exceeding its guidance and analyst expectations. However, the company reduced its full-year profit outlook due to weaker-than-expected demand for its Watchman heart implant device. The revised 2026 adjusted EPS forecast is now between $3.28 and $3.32 per share, down from a previous range of $3.34 to $3.41. Analysts had anticipated full-year earnings of $3.36 per share. The decline in Watchman demand stems from shifting clinical practices where the device is increasingly used alongside other procedures rather than as standalone treatments. Boston Scientific also lowered its organic sales growth forecast for 2026 to between 5% and 6%, down from a prior range of 6.5% to 8%. Despite these challenges, Boston Scientific shares rose nearly 4% in premarket trading following the better-than-expected quarterly results.
Tickers: $BSX
Topics: atrial_fibrillation_treatment cardiovascular medical_devices